Dr. David Valcárcel, member of the Experimental Hematology group at Vall d'Hebron Institute of Research (VHIR), has published in "http://jco.ascopubs.org/content/31/7/916.abstract?sid=ad35644e-f930-438f-8d71-6d40578c39d5" 'Journal of Clinical Oncology', a study which reveals that the bad prognosis of Myelodysplastic Syndrome (MDS), not only is caused by the presence of the monosomal karyotype, but also by multiple genetic alterations. In a report published in 'Diario Médico', VHIR’s researcher explains the results of this joint study of the Spanish Group of MDS, done at 50 Spanish hospitals with 1,054 patients with this disorder. In an interview for the Spanish weekly publication, Dr. Valcárcel assures that the data obtained “is a turning point with the previous studies which suggested that monosomal karyotype worsens the prognosis of patients with MDS, as well as it determines that the accumulation of multiple alterations, which are present in the 85-90% of these patients, is the responsible of the lower survival rates and the higher evolution of acute myeloid leukemia”.The "http://www.gesmd.es/" Spanish Group of MDS works with the aim of promoting and developing research, diagnosis and therapies of this disorder, that in Spain suffer more than 7.000 patients.